Abstract
Failed back surgery syndrome (FBBS†) is characterized by chronic pain that persists following spine surgery. In this review, we discuss the use of spinal cord stimulation (SCS) for FBBS treatment and how the clinical use of SCS may be influenced by private manufacturers. While SCS therapy can be promising for the appropriate patient, there remain knowledge gaps in understanding the full potential of SCS technology for delivering optimal therapeutic benefit. We caution that the use of SCS without a complete understanding of the technology may create exploitative situations that private manufacturers can capitalize on while subjecting patients to potentially unnecessary health and financial burdens.
Original language | English (US) |
---|---|
Pages (from-to) | 323-331 |
Number of pages | 9 |
Journal | Yale Journal of Biology and Medicine |
Volume | 91 |
Issue number | 3 |
State | Published - Sep 1 2018 |
Keywords
- Chronic pain
- Failed back surgery syndrome
- Neurosurgery
- Spinal cord stimulation
- Spine surgery
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)